USA MedTech: Pure Global on The FDA's 'Forever Audit' Rule Titelbild

USA MedTech: Pure Global on The FDA's 'Forever Audit' Rule

USA MedTech: Pure Global on The FDA's 'Forever Audit' Rule

Jetzt kostenlos hören, ohne Abo

Details anzeigen

Über diesen Titel

 The game has changed. This week, the US FDA implemented a 'Total Product Life Cycle' inspection model, shifting regulatory focus from a one-time market approval to a continuous, career-long scrutiny of your medical device. This episode of MedTech Global Insights breaks down what this means for manufacturers and why your old compliance strategies are no longer enough. We explore the practical consequences of this shift. Imagine your device has been on the market for seven years. Are you prepared for an FDA inspector to demand a direct link between a customer complaint filed yesterday and a risk analysis document from the original design phase? This is the new reality, and a gap in that story could put your entire operation at risk. Key Questions Answered: - What is the FDA's new "Total Product Life Cycle" inspection approach? - How does this change the focus of a routine FDA facility audit? - Why is your post-market data now as critical as your initial submission file? - What are the most common gaps in a company's lifecycle documentation? - Can a design choice from five years ago trigger a warning letter today? - How will this US policy impact companies exporting to the United States? - What steps should you take now to ensure your QMS is TPLC-ready? To learn more about navigating these complex regulatory shifts, contact us at info@pureglobal.com, visit https://pureglobal.com/, or explore our free resources at https://pureglobal.ai/.
Noch keine Rezensionen vorhanden